Outcomes of haploidentical vs mismatched unrelated donor HCT with posttransplant cyclophosphamide prophylaxis.

ABSTRACT:

Abstract

Limited data exist comparing haploidentical and mismatched unrelated donor (MMUD) hematopoietic cell transplantation (HCT) with posttransplantation cyclophosphamide for graft-versus-host disease prophylaxis, especially considering donor age. Herein, we report the outcomes of 660 haploidentical and 195 MMUD HCT recipients treated at MD Anderson Cancer Center. Beyond standard Cox proportional hazards modeling, we used inverse probability of treatment weighting (IPTW) and matched-pair analysis, and performed additional analysis by incorporating an external MMUD validation cohort from the Center for International Blood and Marrow Transplant Research (CIBMTR). The primary outcome was overall survival (OS). In multivariable analysis, haploidentical donors had a hazard ratio (HR)

SUBMITTER: Aljawai YM 

PROVIDER: S-EPMC12345264 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature